Assistant Professor, Medicine, University of California, San Francisco, School of Medicine
Hematology
Dr. Jeffrey M. Venstrom, MD
|
|
Give Review
Jeffrey Venstrom is an expert in the field of Hematology. He graduated from Vanderbilt University School of Medicine. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Jeffrey M. Venstrom, MD is a published MD as well. He has 14 publications published. The latest was: KIR and HLA Genotypes Predictive of Low-Affinity Interactions Are Associated with Lower Relapse in Autologous Hematopoietic Cell Transplantation for Acute Myeloid Leuk... Dr. Jeffrey M. Venstrom accepts Medicare payments and is registered with Medicare.gov.
Publications
- KIR and HLA Genotypes Predictive of Low-Affinity Interactions Are Associated with Lower Relapse in Autologous Hematopoietic Cell Transplantation for Acute Myeloid Leuk...
- A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination With Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acu...
- Donor activating KIR2DS1 in Leukemia.
- Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for Acute promyelocytic leukemia: a multi-center analysis.
- CALGB 150905 (Alliance): Rituximab broadens the anti-Lymphoma response by activating unlicensed NK cells.
- Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and oVerall survival in older allogeneic transplant recipients.
- HLA-C-dependent prevention of Leukemia relapse by donor activating KIR2DS1.
- Donor activating KIR3DS1 is associated with decreased Acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation.
- KIR and HLA genotypes are associated with Disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.
- Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hema...
- Survival after pancreas transplantation in patients with diabetes and preserved kidney function.
- Conversion of adipose-derived stem cells into natural killer-like cells with anti-tumor activities in nude mice.
- State of the art: islet transplantation for the cure of type 1 diabetes mellitus.
Schools
Vanderbilt University
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anemia
- Central Nervous System Lymphoma
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Memorial Sloan-Kettering Cancer Center -
Johns Hopkins University -
Vanderbilt University School of Medicine
Hospital
-
UCSF Medical Center
Drug Facts
| NPI NUMBER | 1417100637 | |
| NPPES Provider LastName | VENSTROM | |
| NPPES Provider FirstName | JEFFREY | |
| NPPES Provider ZIPCode | 941430324 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 216.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1417100637 |
| Last Name Of The Provider | VENSTROM |
| First Name Of The Provider | JEFFREY |
| View All |
Similar Doctors
|
|
Dr. Katherine K. Matthay, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Mack Roach III, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Lori A. Kunkel, MD |
|
|
Dr. Carolyn Li, MD |
|
|
Dr. Pamela N. Munster, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles J. Ryan, MD |
|
Dr. James M. Kahn, DO |
|
|
Dr. Willis H. Navarro, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Frank A. Scappaticci, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Nancy K. Valente, MD |
|
|
Dr. Michael T. Byrne, DO |